This website uses cookies

This website uses cookies to ensure you get the best experience. By using our website, you agree to our Privacy Policy

International In-house Counsel Journal logoInternational In-house Counsel Journal logo

Navigating the Headwaters of Intellectual Property Risk in the Pharmaceutical Industry

Abstract

Intellectual property litigation may feel like familiar ground to many competitors in the pharmaceutical drug, medical device, nutraceutical, and other prescription markets. Yet intellectual property laws frequently interact in ways that surprise even well-seasoned competitors, wreaking havoc on key business metrics and ratios. With that concern very much in view, this paper proposes a few considerations in managing towards a more effective and holistic litigation risk management strategy that considers the product and its rivals, relevant business objectives, and the ultimate pathway to success (however that may be defined).

Read Paper

Author

Portrait image of Simon Jenner
Simon Jenner
General Partner, Baker Jenner, USA

Prior to recently forming Baker Jenner, Simon Jenner was Chief Legal Officer for Acella Pharmaceuticals, LLC and Avion Pharmaceuticals, LLC, which are leaders in several important markets. He has significant experience in complex transactions and litigation, including intellectual property and Lanham Act, risk management, industry regulations, and commercial and corporate matters. Simon is practiced in helping corporate clients minimize legal and regulatory risk while maximizing transaction value. Simon graduated in 1999 from College of Arts and Sciences at Case Western Reserve University, Phi Beta Kappa and summa cum laude, with majors in History (with departmental honors), Economics, and Classics. He graduated in 2003 with a JD/MBA from the Thomas Backus School of Law and Weatherhead School of Management, also at Case Western Reserve University.

Company

Baker Jenner logo

Baker Jenner

Baker Jenner LLLP is a business solutions law firm that partners with savvy startups, middle market movers and shakers, and top Fortune companies to help them achieve their strategic business goals while managing various categories of internal and external risk. We know what it means to grow with a business, and to meet business needs at each point in product and corporate life cycles.

Related Papers

Patent Strategies for Attenuated Pathogen Vaccines
Malaria is a major health concern for people traveling to and living in malaria-endemic areas, causing 249 million clinical cases and 608,000 deaths in 2022, numbers essentially unchanged over the...Read more
Portrait image of David Dolberg
David Dolberg
Senior Director of Intellectual Property, Sanaria Inc., USA
Ways to Avoid Having your Patents Cellected*
The Court of Appeals for the Federal Circuit caused frustrations when it decided to affirm the U.S. Patent Office’s findings that claims in four patents were unpatentable because they are...Read more
Portrait image of Tom Irving
Tom Irving
Partner, Marbury Law Group, USA
Portrait image of Michelle E. O'Brien
Michelle E. O'Brien
Partner, Marbury Law Group, USA
Portrait image of Xiaoguang Michelle Gao
Xiaoguang Michelle Gao
Associate VP - Assistant General Patent Counsel , Eli Lilly and Company, USA
Section 112 Requirements for Life Sciences Patents
35 U.S.C. §112(a) of the US Patent Act is one of the integral parts of the quid pro quo patent system that balances the benefit of disclosure of the invention...Read more
Portrait image of Anagha Tendulkar
Anagha Tendulkar
In-house Patent Counsel, Cipla, India
A Current Look at the State of Inequitable Conduct and Other Equitable Concerns
Inequitable conduct is an “equitable defense to patent infringement that, if proved, bars enforcement of a patent. ” Therasense, Inc. v. Becton, Dickinson & Co. , 649 F. 3d 1276,...Read more
Stacy Lewis
Law Clerk, Finnegan, USA